ClinicalTrials.gg
RecruitingNCT05690802TSEPHCCUpdated Jan 19, 2023

The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV

An interventional study of Palonosetron hydrochloride capsules in Nausea and Vomiting, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2022, registered Jan 2023).
  • Started May 2022; still recruiting 4 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,060
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing palonosetron in Nausea — 1 open to participants now, 1 under way, none of them phase 3. Palonosetron · Nausea.

Planned enrollment
2nd of 22
1,060 · median 54
Started
2022
with 1 other
No phase
3 of 22
1 open now
Registered
22nd of 22
by date

Among the 22 studies testing palonosetron in Nausea, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2022, is one of 3 with no phase, and was the 22nd registered.

Nausea

646 studies on the registry are indexed under Nausea; 87 are open to participants now.

Browse Nausea studies →

Open to participants now

1 of the 22 studies testing palonosetron in Nausea is open now, in 1 country.

By country, each count listing its studies:

About palonosetron

Palonosetron: first FDA approval 2003 (ALOXI), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing palonosetron in Nausea, or all of them as a file.
02

Study summary

To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

Read the detailed description

At present, as the mainstream antiemetics of CINV, oral administration is the most commonly used method of drug therapy. Clinical studies showed that there was no difference in the efficacy of 5-HT3 receptor antagonist between different administration routes (oral and intravenous). At the same time, because the oral route is the most convenient, oral preparations provide more and more convenient choices for clinicians and patients. To observe and evaluate the safety and effectiveness of Palonosetron hydrochloride capsule in preventing acute nausea and vomiting caused by moderate emetic chemotherapy; The characteristics of the applicable population, clinical medication and clinical benefits of Palonosetron Hydrochloride Capsules were analyzed.

03

Conditions studied

  • Nausea and Vomiting

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For patients with malignant tumors who can accept chemotherapy, the disease type is not limited. The specific chemotherapy scheme is the chemotherapy scheme with moderate risk of vomiting (for the risk level of vomiting, refer to the 2019 CSCO anti-tumor treatment related nausea and vomiting prevention and treatment guidelines);
  • 18-75 years old, score ≥ 70, and the expected survival time is more than 3 months;
  • Before treatment, , blood routine test, liver and kidney functions and electrolytes were basically normal;
  • All patients signed the form

Exclusion criteria

Exclusion Criteria:

  • Patients with chemotherapy , patients allergic to 5-HT3RA, pregnant women and lactating women;
  • People with digestive tract obstruction; Patients with serious heart disease, liver and kidney disease and metabolic disorder; Patients suffering from epilepsy or using psychotropic and sedative drugs;
  • Used antiemetic drugs or chemicals within 24 hours.Those who have vomited before treatment may have , intracranial hypertension, gastrointestinal obstruction, psychological abnormalities, etc.Patients with factors causing nausea and vomiting.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,060 participants (estimated)

Study arms

  • Experimental
    Palonosetron hydrochloride capsules

    The recommended dose for adults is 0.5mg (1 capsule) for a single oral dose about 1 hour before chemotherapy.

    Drug: Palonosetron hydrochloride capsules

Interventions

  • DrugPalonosetronStudies of PalonosetronPalonosetron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This protocol only stipulates "Palonosetron capsule containing hydrochloric acid protocol", and does not make uniform provisions on the treatment course, and does not interfere with the actual clinical usage and dosage.

    Also known as: Ruoshan ®

06

What researchers measure

Primary outcomes

  1. Any adverse event after treatment

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.

Of 120 non-industry interventional studies with no phase under Nausea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 60 months is above that.

Counting every sponsor, half of 126 studies reached it within 13 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Jan 19, 2023
StartActual
May 16, 2022
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2029
Last update
Jan 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05690802
Lead sponsor
Xijing Hospital
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
May 16, 2022
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2029 (estimated)
Last update
Jan 19, 2023

Study contacts

Liu Hong, master
Contact
hongliu1@fmmu.edu.cn
13709284513
Wei Zhou, master
Contact
252376698@qq.com
13720542643
Liu Hong, master
study chair · Air Force Military Medical University, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palonosetron

Start the discussion